Policy & Regulation
Nanobiotix and Providence Cancer Institute form pre-clinical collaboration to study NBTXR3
11 January 2018 -

Nanomedicine company Nanobiotix (EPA: NANO) has entered into a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, the company announced on Thursday.

NBTXR3 is a first-in-class nanoparticle intended for direct injection into cancerous tumours and activation by radiotherapy.

Providence Cancer Institute is one of the world's leading oncological research centres. The collaboration will see it supply essential preclinical data on the aptitude of NBTXR3 when activated by radiotherapy to induce an antitumoral immune response.

Marka R. Crittenden, M.D., Ph.D., radiation oncologist and director of translational radiation research at the Robert W. Franz Cancer Centre, will head the programme. She said: "Promising pre-clinical data suggests that nanoparticles combined with radiotherapy enhance tumour-specific immune responses and lead to an abscopal response, priming a patient's immune system to attack cancer cells outside of the radiotherapy target area.

"Furthermore, we are absolutely delighted to partner with Nanobiotix to advance our research on this phenomenon and the role NBTXR3 can play in immuno-oncology."



Related Headlines